Friday, October 07, 2022 5:41:21 PM
hankmanhub,
I strongly suspect that with one big pharma company given a closer look at the inside of operations that those others know that they are in an uphill battle to gain access. Not a good time for them or their hedge fund friends. There are plenty of folks with eyes on that can’t get in right now and others who won’t for basically the same reasons. You also know the old saying “Fool me once, shame on you. Fool me twice, shame on me.” Linda has no intention of being fooled twice as Mr. Woodford and Ms Katherine Wolf taught us all a valuable lesson. Linda has taken the tech to nearly full pre revenue value as a partner with bolt on expansion ability to the point that Direct can be fairly validated and value added before buyout or adequately accounted for in any buyout offer now such as the ones being discussed by ATLnsider and no2koolaid.
Those on the outside have no incentive to see their stock collapse by creating increased interest in this company as a major upcoming threat to their revenue streams. In their eyes silence is golden too!; ). Best wishes.
I strongly suspect that with one big pharma company given a closer look at the inside of operations that those others know that they are in an uphill battle to gain access. Not a good time for them or their hedge fund friends. There are plenty of folks with eyes on that can’t get in right now and others who won’t for basically the same reasons. You also know the old saying “Fool me once, shame on you. Fool me twice, shame on me.” Linda has no intention of being fooled twice as Mr. Woodford and Ms Katherine Wolf taught us all a valuable lesson. Linda has taken the tech to nearly full pre revenue value as a partner with bolt on expansion ability to the point that Direct can be fairly validated and value added before buyout or adequately accounted for in any buyout offer now such as the ones being discussed by ATLnsider and no2koolaid.
Those on the outside have no incentive to see their stock collapse by creating increased interest in this company as a major upcoming threat to their revenue streams. In their eyes silence is golden too!; ). Best wishes.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
